Fiche personne
Coordonnées
Institut d'hématologie et d'immunologie
1 place de l'Hôpital
67091 STRASBOURG
03 68 85 40 11
Territoire
Alsace
Statut
Chercheur
Équipes/plateformes
Site web
Projets
Ciblage du microenvironnement tumoral pour améliorer la radiothérapie dans le glioblastome (Radio-TME-Targeting)
2024 - Porteur du projet : Dr OREND Gertraud
Détermination de l'impact de la molécule de matrice extracellulaire ténascine-C sur les fibroblastes réticulaires dans les tumeurs de la tête et du cou
2022 - Porteur du projet : Dr OREND Gertraud
Restoration of anti-tumor immunity by targeting the extracellular matrix with CAR T cells
2022 - Porteur du projet : Dr OREND Gertraud - Partenaire : Dr FERRAND Christophe
Détermination de l'impact de la molécule de matrice extracellulaire ténascine-C sur les fibroblastes réticulaires dans les tumeurs de la tête et du cou
2021 - Porteur du projet : Dr OREND Gertraud
Caractérisation moléculaire et fonctionnelle des niches matricielles riches en Tenascin-C au cours de l'évolution de l'immunité tumorale (TEN-MAX)
2020 - Porteur du projet : Dr OREND Gertraud
Understanding and REFINING the influence of RADIOtherapy on the tumor microenvironment, by applying novel models to REDUCE and REPLACE animal models (RADIO-3R)
2020 - Porteur du projet : Pr NOEL Georges - Partenaire : Dr OREND Gertraud
Détermination du rôle d'un axe de signalisation ténascine-C / CXCL12 dans le cancer humain et dans un nouveau modèle de progression du cancer du sein
2019 - Porteur du projet : Dr OREND Gertraud
Comprendre l’axe ténascine-C/TRAIL pour améliorer l’élimination des cellules cancéreuses
2018 - Porteur du projet : Dr OREND Gertraud
Détermination du rôle d'un axe de signalisation ténascine-C / CXCL12 dans le cancer humain et dans un nouveau modèle de progression du cancer du sein
2018 - Porteur du projet : Dr OREND Gertraud
Analyse du rôle de la ténascine C, molécule de la matrice extracellulaire, dans les carcinomes épidermoïdes oraux par de nouveaux modèles tumoraux immunocompétents
2016 - Porteur du projet : Dr OREND Gertraud
Analyse du rôle de la ténascine C, molécule de la matrice extracellulaire, dans les carcinomes épidermoïdes oraux par de nouveaux modèles tumoraux immunocompétents
2015 - Porteur du projet : Dr OREND Gertraud
La tenascine-C et les plaquettes : complices potentiels dans la formation de métastases pulmonaires dans le cancer du sein (TEN-PLA-MET)
2013 - Porteur du projet : Dr OREND Gertraud - Partenaire : Dr CHARBONNIERE Loïc , Pr CHENARD Marie-Pierre , Pr LAQUERRIERE Patrice , Dr MANGIN Pierre
Mécanismes moléculaires régulant DKK1 via la Ténascine-C et son impact sur l'écosystème tumoral
2013 - Porteur du projet : Dr OREND Gertraud
Molecular mechanism of Tenascin-C dependent tumor angiogenesis
2012 - Porteur du projet : Dr OREND Gertraud
Etude de la Tenascine-C dans les mécanismes d’induction des cancers du sein et de métastases, utilisation de l’imagerie in vivo
2010 - Porteur du projet : Dr OREND Gertraud - Partenaire : Dr BRASSE David , Pr MATHELIN Carole
Implication of α6β4 integrin in inflammation and colorectal tumorigenesis (INTADK)
2008 - Porteur du projet : Dr GEORGES-LABOUESSE Elisabeth - Partenaire : Dr NEUVILLE Agnès , Dr OREND Gertraud
Early determination of aggressiveness of primary tumors (RIO2007)
2007 - Porteur du projet : Dr RIO Marie-Christine - Partenaire : Pr ABECASSIS Joseph , Pr BIREMBAUT Philippe , Pr DIEBOLD Marie-Danièle , Dr FREUND Jean-Noël , Dr GAUB Marie-Pierre , Dr GHNASSIA Jean-Pierre , Dr GUERIN Eric , Pr HAIECH Jacques , Pr JEANNESSON Pierre , Dr KASTNER Philippe , Pr MANFAIT Michel , Pr MAQUART François-Xavier , Dr NEUVILLE Agnès , Dr OREND Gertraud , Pr PLENAT François , Dr VAN DORSSELAER Alain , Pr VIGNAUD Jean-Michel , Dr VOEGEL Jean-Claude , Dr WASYLYK Bohdan
Publications
Granzyme B cleaves Tenascin-C to release its C-terminal domain in rheumatoid arthritis.
Aubert A, Liu A, Kao M, Goeres J, Richardson KC, Nierves L, Jung K, Nabai L, Zhao H, Orend G, Krawetz R, Lange PF, Younger A, Chan J, Granville DJ
JCI Insight. 2024 10 17;:
Targeting the MAtrix REgulating MOtif abolishes several hallmarks of cancer, triggering antitumor immunity.
Li C, Kaur A, Pavlidaki A, Spenlé C, Rajnpreht I, Donnadieu E, Salomé N, Molitor A, Carapito R, Wack F, Erne W, Lefebvre O, Averous G, Mitrentsi I, Loustau T, Orend G
Proc Natl Acad Sci U S A. 2024 10 15;121(42):e2404485121
Tenascin-C targeting strategies in cancer.
Dhaouadi S, Bouhaouala-Zahar B, Orend G
Matrix Biol. 2024 04 18;:
Investigating Chemokine-Matrix Networks in Breast Cancer: Tenascin-C Sets the Tone for CCL2.
Gschwandtner M, Gammage AN, Deligne C, Mies LFM, Domaingo A, Murdamoothoo D, Loustau T, Schwenzer A, Derler R, Carapito R, Koch M, Mörgelin M, Orend G, Kungl AJ, Midwood KS
Int J Mol Sci. 2023 05 6;24(9):
How the mechanobiology orchestrates the iterative and reciprocal ECM-cell cross-talk that drives microtissue growth.
Benn MC, Pot SA, Moeller J, Yamashita T, Fonta CM, Orend G, Kollmannsberger P, Vogel V
Sci Adv. 2023 03 29;9(13):eadd9275
Infiltrating CD8+ T cells and M2 macrophages are retained in tumor matrix tracks enriched in low tension fibronectin fibers.
Fonta CM, Loustau T, Li C, Surendran SP, Hansen U, Murdamoothoo D, Benn MC, Velazquez-Quesada I, Carapito R, Orend G, Vogel V
Matrix Biol. 2023 01 17;:
Dicer1 deficient mice exhibit premature aging and metabolic perturbations in adipocytes.
De Cauwer A, Loustau T, Erne W, Pichot A, Molitor A, Stemmelen T, Carapito R, Orend G, Bahram S, Georgel P
iScience. 2022 10 21;25(10):105149
Advances on the roles of tenascin-C in cancer.
Yilmaz A, Loustau T, Salomé N, Poilil Surendran S, Li C, Tucker RP, Izzi V, Lamba R, Koch M, Orend G
J Cell Sci. 2022 09 15;135(18):
Modulating tenascin-C functions by targeting the MAtrix REgulating MOtif, "MAREMO".
Loustau T, Abou-Faycal C, Erne W, Zur Wiesch PA, Ksouri A, Imhof T, Mörgelin M, Li C, Mathieu M, Salomé N, Crémel G, Dhaouadi S, Bouhaouala-Zahar B, Koch M, Orend G
Matrix Biol. 2022 Feb 25;:
An adapted passive model of anti-MPO dependent crescentic glomerulonephritis reveals matrix dysregulation and is amenable to modulation by CXCR4 inhibition.
Faycal CA, Oszwald A, Feilen T, Contreras MJC, Schilling O, Loustau T, Steinbach F, Schachner H, Langer B, Heeringa P, Rees AJ, Orend G, Kain R
Matrix Biol. 2022 Jan 12;:
Tenascin C Has a Modest Protective Effect on Acute Lung Pathology during Methicillin-Resistant Staphylococcus aureus-Induced Pneumonia in Mice.
Meijer MT, de Vos AF, Peters Sengers H, Scicluna BP, Roelofs JJ, Abou Fayçal C, Uhel F, Orend G, van der Poll T
Microbiol Spectr. 2021 Jul 28;:e0020721
Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression.
Murdamoothoo D, Sun Z, Yilmaz A, Riegel G, Abou-Faycal C, Deligne C, Velazquez-Quesada I, Erne W, Nascimento M, Mörgelin M, Cremel G, Paul N, Carapito R, Veber R, Dumortier H, Yuan J, Midwood KS, Loustau T, Orend G
EMBO Mol Med. 2021 May 14;:e13270
Did Tenascin-C Co-Evolve With the General Immune System of Vertebrates?
Orend G, Tucker RP
Front Immunol. 2021 ;12:663902
Editorial: Tenascins - Key Players in Tissue Homeostasis and Defense.
Yoshida KI, Midwood KS, Orend G
Front Immunol. 2021 ;12:834353
Impact of Tenascin-C on Radiotherapy in a Novel Syngeneic Oral Squamous Cell Carcinoma Model With Spontaneous Dissemination to the Lymph Nodes.
Spenlé C, Loustau T, Burckel H, Riegel G, Abou Faycal C, Li C, Yilmaz A, Petti L, Steinbach F, Ahowesso C, Jost C, Paul N, Carapito R, Noël G, Anjuère F, Salomé N, Orend G
Front Immunol. 2021 ;12:636108
Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies.
Dhaouadi S, Ben Abderrazek R, Loustau T, Abou-Faycal C, Ksouri A, Erne W, Murdamoothoo D, Mörgelin M, Kungl A, Jung A, Ledrappier S, Benlasfar Z, Bichet S, Chiquet-Ehrismann R, Hendaoui I, Orend G, Bouhaouala-Zahar B
Front Immunol. 2021 ;12:635166
Tenascin-C Deficiency Is Associated With Reduced Bacterial Outgrowth During -Evoked Pneumosepsis in Mice.
Meijer MT, de Vos AF, Scicluna BP, Roelofs JJ, Abou Fayçal C, Orend G, Uhel F, van der Poll T
Front Immunol. 2021 ;12:600979
ECM deposition is driven by caveolin-1-dependent regulation of exosomal biogenesis and cargo sorting.
Albacete-Albacete L, Navarro-Lérida I, López JA, Martín-Padura I, Astudillo AM, Ferrarini A, Van-Der-Heyden M, Balsinde J, Orend G, Vázquez J, Del Pozo MÁ
J Cell Biol. 2020 Nov 2;219(11):
Tenascin-C orchestrates an immune suppressive tumor microenvironment in oral squamous cell carcinoma.
Spenlé C, Loustau T, Murdamoothoo D, Erne W, Beghelli-de la Forest Divonne S, Veber R, Petti L, Bourdely P, Mörgelin M, Brauchle EM, Crémel G, Randrianarisoa V, Camara A, Rekima S, Schaub S, Nouhen K, Imhof T, Hansen U, Paul N, Carapito R, Pythoud N, Hirschler A, Carapito C, Dumortier H, Mueller CG, Koch M, Schenke-Layland K, Kon S, Sudaka A, Anjuere F, Van Obberghen-Schilling E, Orend G
Cancer Immunol Res. 2020 Jul 14;:
Generation and characterization of dromedary Tenascin-C and Tenascin-W specific antibodies.
Dhaouadi S, Murdamoothoo D, Tounsi A, Erne W, Benabderrazek R, Benlasfar Z, Hendaoui L, Chiquet-Ehrismann R, Boubaker S, Orend G, Hendaoui I, Bouhaouala-Zahar B
Biochem. Biophys. Res. Commun.. 2020 Jun 24;:
Matrix-targeting immunotherapy controls tumor growth and spread by switching macrophage phenotype.
Deligne C, Murdamoothoo D, Gammage AN, Gschwandtner M, Erne W, Loustau T, Marzeda AM, Carapito R, Paul N, Velázquez-Quesada I, Mazzier I, Sun Z, Orend G, Midwood KS
Cancer Immunol Res. 2020 Jan 15;:
Functionalized Coat Protein Monomers and Oligomers as Nanocarriers for Anti-Cancer Peptides.
Gamper C, Spenlé C, Boscá S, van der Heyden M, Erhardt M, Orend G, Bagnard D, Heinlein M
Cancers (Basel). 2019 Oct 22;11(10):
Tenascin-C increases lung metastasis by impacting blood vessel invasions.
Sun Z, Velázquez-Quesada I, Murdamoothoo D, Ahowesso C, Yilmaz A, Spenlé C, Averous G, Erne W, Oberndorfer F, Oszwald A, Kain R, Bourdon C, Mangin P, Deligne C, Midwood K, Abou-Faycal C, Lefebvre O, Klein A, van der Heyden M, Chenard MP, Christofori G, Mathelin C, Loustau T, Hussenet T, Orend G
Matrix Biol.. 2019 Jul 6;:
Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinoma.
Mammadova-Bach E, Rupp T, Spenlé C, Jivkov I, Shankaranarayanan P, Klein A, Pisarsky L, Méchine-Neuville A, Cremel G, Kedinger M, De Wever O, Ambartsumian N, Robine S, Pencreach E, Guenot D, Simon-Assmann P, Goetz JG, Orend G, Lefebvre O
Biol. Cell. 2018 Jun 15;:
Periostin Limits Tumor Response to VEGFA Inhibition.
Keklikoglou I, Kadioglu E, Bissinger S, Langlois B, Bellotti A, Orend G, Ries CH, De Palma M
Cell Rep. 2018 Mar 6;22(10):2530-2540
Tenascin-C Promotes Tumor Cell Migration and Metastasis through Integrin α9β1-Mediated YAP Inhibition.
Sun Z, Schwenzer A, Rupp T, Murdamoothoo D, Vegliante R, Lefebvre O, Klein A, Hussenet T, Orend G
Cancer Res.. 2018 Feb 15;78(4):950-961
How to detect and purify tenascin-C.
Giblin SP, Murdamoothoo D, Deligne C, Schwenzer A, Orend G, Midwood KS
Methods Cell Biol.. 2018 ;143:371-400
Investigating cell-type specific functions of tenascin-C.
Murdamoothoo D, Schwenzer A, Kant J, Rupp T, Marzeda A, Midwood K, Orend G
Methods Cell Biol.. 2018 ;143:401-428
Counterbalancing anti-adhesive effects of Tenascin-C through fibronectin expression in endothelial cells.
Radwanska A, Grall D, Schaub S, Divonne SBF, Ciais D, Rekima S, Rupp T, Sudaka A, Orend G, Obberghen-Schilling EV
Sci Rep. 2017 Oct;7(1):12762
Tenascin-C at a glance.
Midwood KS, Chiquet M, Tucker RP, Orend G
J. Cell. Sci.. 2016 Dec;129(23):4321-4327
Tenascin-C Orchestrates Glioblastoma Angiogenesis by Modulation of Pro- and Anti-angiogenic Signaling.
Rupp T, Langlois B, Koczorowska MM, Radwanska A, Sun Z, Hussenet T, Lefebvre O, Murdamoothoo D, Arnold C, Klein A, Biniossek ML, Hyenne V, Naudin E, Velazquez-Quesada I, Schilling O, Van Obberghen-Schilling E, Orend G
Cell Rep. 2016 Dec;17(10):2607-2619
Inhibition of PlexA1-mediated brain tumor growth and tumor-associated angiogenesis using a transmembrane domain targeting peptide.
Jacob L, Sawma P, Garnier N, Meyer LA, Fritz J, Hussenet T, Spenlé C, Goetz J, Vermot J, Fernandez A, Baumlin N, Aci-Sèche S, Orend G, Roussel G, Crémel G, Genest M, Hubert P, Bagnard D
Oncotarget. 2016 09;7(36):57851-57865
Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9.
Mammadova-Bach E, Zigrino P, Brucker C, Bourdon C, Freund M, De Arcangelis A, Abrams SI, Orend G, Gachet C, Mangin PH
JCI Insight. 2016 Sep;1(14):e88245
Inhibition of primary breast tumor growth and metastasis using a neuropilin-1 transmembrane domain interfering peptide.
Arpel A, Gamper C, Spenlé C, Fernandez A, Jacob L, Baumlin N, Laquerriere P, Orend G, Crémel G, Bagnard D
Oncotarget. 2016 Aug;7(34):54723-54732
Autonomous Extracellular Matrix Remodeling Controls a Progressive Adaptation in Muscle Stem Cell Regenerative Capacity during Development.
Tierney MT, Gromova A, Sesillo FB, Sala D, Spenlé C, Orend G, Sacco A
Cell Rep. 2016 Mar;14(8):1940-52
A hypermorphic epithelial beta-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations.
Buchert M, Rohde F, Eissmann M, Tebbutt N, Williams B, Tan CW, Owen A, Hirokawa Y, Gnann A, Orend G, Orner G, Dashwood RH, Heath JK, Ernst M, Janssen KP
Dis Model Mech. 2015 Aug 6. pii: dmm.019844.
Spatial organization of the tenascin-C microenvironment in experimental and human cancer.
Spenle C, Gasser I, Saupe F, Janssen KP, Arnold C, Klein A, van der Heyden M, Mutterer J, Neuville-Mechine A, Chenard MP, Guenot D, Esposito I, Slotta-Huspenina J, Ambartsumian N, Simon-Assmann P, Orend G
Cell Adh Migr. 2015 Jan 22:0.
Special issue of Cell Adhesion & Migration on Tenascins: Defining their role in tissue homeostasis and cancer.
Midwood K, Orend G
Cell Adh Migr. 2015 Jan 2;9(1-2):1-3
Tenascin-C: exploitation and collateral damage in cancer management.
Spenle C, Saupe F, Midwood K, Burkel H, Noel G, Orend G
Cell Adh Migr. 2015 Jan 8:0.
Phosphonated chelates for nuclear imaging.
Abada S, Lecointre A, Christine C, Ehret-Sabatier L, Saupe F, Orend G, Brasse D, Ouadi A, Hussenet T, Laquerrière P, Elhabiri M, Charbonnière LJ
Org. Biomol. Chem.. 2014 Dec;12(47):9601-20
AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients.
Langlois B, Saupe F, Rupp T, Arnold C, van der Heyden M, Orend G, Hussenet T
Oncotarget. 2014 Nov 15;5(21):10529-45.
Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis.
Arpel A, Sawma P, Spenle C, Fritz J, Meyer L, Garnier N, Velazquez-Quesada I, Hussenet T, Aci-Seche S, Baumlin N, Genest M, Brasse D, Hubert P, Cremel G, Orend G, Laquerriere P, Bagnard D
Cell Rep. 2014 Sep 25;8(6):1714-21
Tenascins in stem cell niches.
Chiquet-Ehrismann R, Orend G, Chiquet M, Tucker RP, Midwood KS
Matrix Biol. 2014 Jul;37:112-23
Loss of SPARC protects hematopoietic stem cells from chemotherapy toxicity by accelerating their return to quiescence.
Ehninger A, Boch T, Medyouf H, Mudder K, Orend G, Trumpp A
Blood. 2014 Jun 26;123(26):4054-63
The laminin response in inflammatory bowel disease: protection or malignancy?
Spenle C, Lefebvre O, Lacroute J, Mechine-Neuville A, Barreau F, Blottiere HM, Duclos B, Arnold C, Hussenet T, Hemmerle J, Gullberg D, Kedinger M, Sorokin L, Orend G, Simon-Assmann P
PLoS One. 2014 Oct 27;9(10):e111336
Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model.
Saupe F, Schwenzer A, Jia Y, Gasser I, Spenle C, Langlois B, Kammerer M, Lefebvre O, Hlushchuk R, Rupp T, Marko M, van der Heyden M, Cremel G, Arnold C, Klein A, Simon-Assmann P, Djonov V, Neuville-Mechine A, Esposito I, Slotta-Huspenina J, Janssen KP, de Wever O, Christofori G, Hussenet T, Orend G
Cell Rep. 2013 Oct 31;5(2):482-92
Laminin alpha5 guides tissue patterning and organogenesis.
Spenle C, Simon-Assmann P, Orend G, Miner JH
Cell Adh Migr. 2013 Jan-Feb;7(1):90-100
Synthesis of an activated phosphonated bifunctional chelate with potential for PET imaging and radiotherapy.
Christine C, Koubemba M, Shakir S, Clavier S, Ehret-Sabatier L, Saupe F, Orend G, Charbonniere LJ
Org Biomol Chem. 2012 Dec 14;10(46):9183-90
Dysregulation of laminins in intestinal inflammation.
Spenle C, Hussenet T, Lacroute J, Lefebvre O, Kedinger M, Orend G, Simon-Assmann P
Pathol Biol (Paris). 2012 Feb;60(1):41-7
Abnormal Wnt and PI3Kinase signaling in the malformed intestine of lama5 deficient mice.
Ritie L, Spenle C, Lacroute J, Bolcato-Bellemin AL, Lefebvre O, Bole-Feysot C, Jost B, Klein A, Arnold C, Kedinger M, Bagnard D, Orend G, Simon-Assmann P
PLoS One. 2012;7(5):e37710
The adhesion modulating properties of tenascin-W.
Brellier F, Martina E, Chiquet M, Ferralli J, van der Heyden M, Orend G, Schittny JC, Chiquet-Ehrismann R, Tucker RP
Int J Biol Sci. 2012;8(2):187-94
Functional role of laminin alpha1 chain during cerebellum development.
Heng C, Lefebvre O, Klein A, Edwards MM, Simon-Assmann P, Orend G, Bagnard D
Cell Adh Migr. 2011 Nov-Dec;5(6):480-9.
Advances in tenascin-C biology.
Midwood KS, Hussenet T, Langlois B, Orend G
Cell Mol Life Sci. 2011 Oct;68(19):3175-99
Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth.
Van Obberghen-Schilling E, Tucker RP, Saupe F, Gasser I, Cseh B, Orend G
Int J Dev Biol. 2011;55(4-5):511-25.
Novel function of tenascin-C, a matrix protein relevant to atherosclerosis, in platelet recruitment and activation under flow.
Schaff M, Receveur N, Bourdon C, Wurtz V, Denis CV, Orend G, Gachet C, Lanza F, Mangin PH
Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):117-24
Role of laminins in physiological and pathological angiogenesis.
Simon-Assmann P, Orend G, Mammadova-Bach E, Spenle C, Lefebvre O
Int J Dev Biol. 2011;55(4-5):455-65.
RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 and {alpha}5{beta}1 integrin co-signaling.
Wang Z, Collighan RJ, Gross SR, Danen EH, Orend G, Telci D, Griffin M
J Biol Chem. 2010 Dec 17;285(51):40212-29
The role of tenascin-C in tissue injury and tumorigenesis.
Midwood KS, Orend G
J Cell Commun Signal. 2009 Dec;3(3-4):287-310
Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease.
Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, Brennan F, Foxwell B
Nat Med. 2009 Jul;15(7):774-80
Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization.
Lange K, Kammerer M, Hegi ME, Grotegut S, Dittmann A, Huang W, Fluri E, Yip GW, Gotte M, Ruiz C, Orend G
Cancer Res. 2007 Jul 1;67(13):6163-73.
Tenascin-C induced signaling in cancer.
Orend G, Chiquet-Ehrismann R
Cancer Lett. 2006 Dec 8;244(2):143-63
CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis.
Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H, Sleeman JP
Cancer Res. 2005 Dec 1;65(23):10783-93.
Potential oncogenic action of tenascin-C in tumorigenesis.
Orend G
Int J Biochem Cell Biol. 2005 May;37(5):1066-83
Growth promoting signaling by tenascin-C [corrected]
Ruiz C, Huang W, Hegi ME, Lange K, Hamou MF, Fluri E, Oakeley EJ, Chiquet-Ehrismann R, Orend G
Cancer Res. 2004 Oct 15;64(20):7377-85.